Logo image of CANF

CAN FITE BIOPHARMA LTD-ADR (CANF) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:CANF - US13471N3008 - ADR

4.14 USD
-0.22 (-5.05%)
Last: 1/9/2026, 8:04:00 PM
4.19 USD
+0.05 (+1.21%)
Pre-Market: 1/12/2026, 9:16:03 AM
Fundamental Rating

3

Overall CANF gets a fundamental rating of 3 out of 10. We evaluated CANF against 528 industry peers in the Biotechnology industry. While CANF seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, CANF is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CANF has reported negative net income.
CANF had a negative operating cash flow in the past year.
CANF had negative earnings in each of the past 5 years.
CANF had a negative operating cash flow in each of the past 5 years.
CANF Yearly Net Income VS EBIT VS OCF VS FCFCANF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -102.07%, CANF is doing worse than 75.57% of the companies in the same industry.
With a Return On Equity value of -188.34%, CANF is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -102.07%
ROE -188.34%
ROIC N/A
ROA(3y)-90.8%
ROA(5y)-101.33%
ROE(3y)-164.91%
ROE(5y)-170%
ROIC(3y)N/A
ROIC(5y)N/A
CANF Yearly ROA, ROE, ROICCANF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CANF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CANF Yearly Profit, Operating, Gross MarginsCANF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

6

2. Health

2.1 Basic Checks

CANF does not have a ROIC to compare to the WACC, probably because it is not profitable.
CANF has more shares outstanding than it did 1 year ago.
CANF has more shares outstanding than it did 5 years ago.
CANF has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CANF Yearly Shares OutstandingCANF Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
CANF Yearly Total Debt VS Total AssetsCANF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

CANF has an Altman-Z score of -21.59. This is a bad value and indicates that CANF is not financially healthy and even has some risk of bankruptcy.
CANF has a Altman-Z score of -21.59. This is amonst the worse of the industry: CANF underperforms 83.71% of its industry peers.
There is no outstanding debt for CANF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -21.59
ROIC/WACCN/A
WACC8.6%
CANF Yearly LT Debt VS Equity VS FCFCANF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

A Current Ratio of 3.60 indicates that CANF has no problem at all paying its short term obligations.
CANF has a Current ratio of 3.60. This is comparable to the rest of the industry: CANF outperforms 42.99% of its industry peers.
A Quick Ratio of 3.60 indicates that CANF has no problem at all paying its short term obligations.
CANF has a Quick ratio of 3.60. This is comparable to the rest of the industry: CANF outperforms 45.08% of its industry peers.
Industry RankSector Rank
Current Ratio 3.6
Quick Ratio 3.6
CANF Yearly Current Assets VS Current LiabilitesCANF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.00% over the past year.
Looking at the last year, CANF shows a decrease in Revenue. The Revenue has decreased by -9.29% in the last year.
The Revenue for CANF have been decreasing by -19.81% on average. This is quite bad
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
Revenue 1Y (TTM)-9.29%
Revenue growth 3Y-7.55%
Revenue growth 5Y-19.81%
Sales Q2Q%-36.08%

3.2 Future

The Earnings Per Share is expected to grow by 25.99% on average over the next years. This is a very strong growth
CANF is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 35.00% yearly.
EPS Next Y13.95%
EPS Next 2Y41.42%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue Next Year0%
Revenue Next 2Y-10.92%
Revenue Next 3Y35%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CANF Yearly Revenue VS EstimatesCANF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M
CANF Yearly EPS VS EstimatesCANF Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2023 2024 2025 -200 -400 -600 -800

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CANF. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CANF Price Earnings VS Forward Price EarningsCANF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CANF Per share dataCANF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as CANF's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

CANF does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CAN FITE BIOPHARMA LTD-ADR

NYSEARCA:CANF (1/9/2026, 8:04:00 PM)

Premarket: 4.19 +0.05 (+1.21%)

4.14

-0.22 (-5.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-28 2025-08-28
Earnings (Next)04-12 2026-04-12/bmo
Inst Owners2.01%
Inst Owner Change0%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap70.68M
Revenue(TTM)674.00K
Net Income(TTM)-7.88M
Analysts80
Price TargetN/A
Short Float %0.19%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-45.77%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)7.61%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 104.87
P/FCF N/A
P/OCF N/A
P/B 16.89
P/tB 16.89
EV/EBITDA N/A
EPS(TTM)-0.72
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS0.04
BVpS0.25
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -102.07%
ROE -188.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-90.8%
ROA(5y)-101.33%
ROE(3y)-164.91%
ROE(5y)-170%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.9%
Cap/Sales 0.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.6
Quick Ratio 3.6
Altman-Z -21.59
F-Score3
WACC8.6%
ROIC/WACCN/A
Cap/Depr(3y)49.68%
Cap/Depr(5y)88.86%
Cap/Sales(3y)0.71%
Cap/Sales(5y)1.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
EPS Next Y13.95%
EPS Next 2Y41.42%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue 1Y (TTM)-9.29%
Revenue growth 3Y-7.55%
Revenue growth 5Y-19.81%
Sales Q2Q%-36.08%
Revenue Next Year0%
Revenue Next 2Y-10.92%
Revenue Next 3Y35%
Revenue Next 5YN/A
EBIT growth 1Y0.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.49%
OCF growth 3YN/A
OCF growth 5YN/A

CAN FITE BIOPHARMA LTD-ADR / CANF FAQ

Can you provide the ChartMill fundamental rating for CAN FITE BIOPHARMA LTD-ADR?

ChartMill assigns a fundamental rating of 3 / 10 to CANF.


What is the valuation status of CAN FITE BIOPHARMA LTD-ADR (CANF) stock?

ChartMill assigns a valuation rating of 1 / 10 to CAN FITE BIOPHARMA LTD-ADR (CANF). This can be considered as Overvalued.


Can you provide the profitability details for CAN FITE BIOPHARMA LTD-ADR?

CAN FITE BIOPHARMA LTD-ADR (CANF) has a profitability rating of 0 / 10.


Can you provide the financial health for CANF stock?

The financial health rating of CAN FITE BIOPHARMA LTD-ADR (CANF) is 6 / 10.